Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098332 · ClinicalTrials.gov registry record · Phase 1
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00098332: Completed Phase 1 study, sponsored by BioCryst Pharmaceuticals.
NCT00098332 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00098332, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma.
Interventions
- DRUG forodesine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
What the finished NCT00098332 record still lists
NCT00098332 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which forodesine hydrochloride is the first listed.
NCT00098332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00098332 about?
NCT00098332 is a clinical study titled "Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma". RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell l...
What is the current status of trial NCT00098332?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00098332?
The interventions under investigation include: forodesine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00098332?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia